Comparative Pharmacology
Head-to-head clinical analysis: DEFEROXAMINE MESYLATE versus JADENU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFEROXAMINE MESYLATE versus JADENU.
DEFEROXAMINE MESYLATE vs JADENU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deferoxamine chelates iron by forming a stable complex (ferrioxamine) that is excreted renally, preventing iron from catalyzing free radical formation and reducing tissue damage.
Deferasirox is an oral iron chelator that binds trivalent iron (Fe3+) with high affinity, forming a stable complex that is excreted primarily in the feces.
For acute iron intoxication: 1 g intramuscularly initially, then 0.5 g every 4 hours for 2 doses, then 0.5 g every 4-12 hours up to a maximum of 6 g/day. For chronic iron overload: 20-40 mg/kg/day subcutaneously over 8-12 hours via infusion pump, or 1-2 g intravenously over 8-24 hours.
30 mg/kg once daily orally, up to a maximum of 60 mg/kg/day, for iron chelation in patients with thalassemia or other chronic iron overload; dose should be adjusted based on serum ferritin levels and therapeutic response.
None Documented
None Documented
Terminal elimination half-life is approximately 5-6 hours for the parent drug after IM or IV administration. The half-life of ferrioxamine is about 6 hours. Clinical context: repeated dosing may be needed for sustained chelation.
Terminal elimination half-life is 8-16 hours (mean ~12 h) in patients with transfusional iron overload, allowing once-daily dosing.
Primarily renal; within 24 hours, approximately 50% of an intramuscular dose is excreted as unchanged drug and 20% as ferrioxamine (the iron chelate). Biliary excretion is minor (<10%).
Primarily fecal (hepatobiliary) ~75-90% as unchanged drug and iron complex; renal excretion of deferasirox is minimal (<5% unchanged).
Category A/B
Category C
Iron Chelator
Iron Chelator